Lesson
Start With Oxygen Delivery and Time Course
Anemia is reduced red cell oxygen carrying capacity, not one diagnosis. The urgency depends on hemodynamic stability, active bleeding, rate of change, symptoms, cardiopulmonary reserve, and tissue perfusion.
- Oxygen delivery
- Acute or chronic
- Production
- Blood loss
- Hemolysis
- Reticulocytes
Treat active bleeding, instability, ischemia, and hypoxemia immediately
Use history, reticulocytes, smear, and laboratory pattern
A rapid fall can be dangerous before the number reaches a fixed threshold
Name the disease process that produced the anemia
Recognize instability before subtype
Active hemorrhage, hypotension, syncope, ischemic chest symptoms, severe dyspnea, hypoxemia, altered mental status, or a rapid hemoglobin fall requires urgent escalation. Source control, resuscitation, type and screen, and serial assessment proceed while the cause is investigated.
Separate production, loss, and destruction
Low marrow output suggests nutrient deficiency, kidney disease, inflammation, marrow failure, or suppression. Blood loss can be obvious or occult. Hemolysis shortens red cell survival and produces a different biochemical and smear pattern.
Use the reticulocyte response correctly
Reticulocytes show marrow response, but the percentage must be interpreted relative to the degree of anemia. Recent hemorrhage, transfusion, treatment, marrow substrate, and timing alter the result.
Keep symptoms in context
Fatigue and dyspnea are nonspecific. Pallor, pica, glossitis, neuropathy, jaundice, dark urine, bleeding, infection, weight loss, and bone pain can redirect the differential.
Do not transfuse by number alone
Transfusion integrates symptoms, instability, active bleeding, ischemia, chronicity, alternatives, alloimmunization, volume risk, and patient values. A fixed threshold does not replace clinical judgment.
Quick check
Lesson
Use Cell Size as a Map, Not a Verdict
MCV narrows the differential but cannot establish the cause. RDW, reticulocytes, smear, other cell lines, biochemical tests, clinical history, and mixed processes determine what the average cell size conceals.
- Microcytic
- Normocytic
- Macrocytic
- RDW
- Smear
- Mixed anemia
Separate deficiency, restriction, thalassemia, toxin, and sideroblast patterns
Divide underproduction from blood loss or destruction
Protect against B12 neurologic injury while evaluating other causes
Use RDW, smear, and parallel nutrient testing
Interrogate microcytosis
Iron deficiency is common, but thalassemia, inflammatory iron restriction, sideroblastic disease, and lead exposure remain alternatives. Ferritin, TSAT, RBC pattern, RDW, smear, history, and selected hemoglobin or toxin testing refine the diagnosis.
Do not dismiss normocytic anemia
Early iron or vitamin deficiency, CKD, inflammation, acute blood loss, hemolysis, marrow failure, and mixed disease can all present with a normal MCV. Reticulocyte behavior separates many underproduction and destruction pathways.
Protect the macrocytic differential
Vitamin B12 and folate deficiency produce megaloblastic patterns, while alcohol, liver disease, hypothyroidism, marrow disorders, medication exposure, and reticulocytosis can increase cell size without the same mechanism.
Find mixed disease
A normal MCV can average a microcytic and macrocytic population. Increased RDW, smear heterogeneity, nutritional risk, kidney disease, inflammation, bleeding, or recent transfusion should prevent premature closure.
Escalate abnormal marrow signals
Pancytopenia, severe neutropenia or thrombocytopenia, blasts, dysplasia, unexplained splenomegaly, or a persistently unexplained pattern requires hematology evaluation rather than repeated empiric supplementation.
Quick check
Lesson
Diagnose Iron Deficiency and Explain Why It Happened
Iron studies describe stores and availability, but inflammation can change their meaning. Confirm the pattern, identify ongoing loss or impaired absorption, and define a measurable response before choosing replacement.
- Ferritin
- TSAT
- TIBC
- Hepcidin
- Blood loss
- Malabsorption
Interpret with inflammation, liver disease, infection, malignancy, and recent iron
Estimate iron available to erythropoiesis in the current setting
Investigate menstrual, gastrointestinal, dietary, and malabsorptive causes
Confirm exposure, marrow response, and source control
Read ferritin in context
Low ferritin strongly supports depleted stores. A normal or elevated value can coexist with restricted iron availability during inflammation, infection, liver disease, CKD, or malignancy. TSAT and the clinical setting prevent false reassurance.
Find the source
Heavy menstrual bleeding, gastrointestinal blood loss, pregnancy, repeated donation, poor intake, celiac disease, inflammatory bowel disease, bariatric or gastric surgery, and acid suppression are common pathways. Replacement does not cancel the need for age and risk appropriate bleeding evaluation.
Separate absolute from functional deficiency
Absolute deficiency reflects depleted stores. Functional restriction reflects impaired delivery to marrow, often through inflammation and hepcidin. The treatment threshold and route depend on the disease setting.
Define response
A rising reticulocyte response and hemoglobin trajectory support effective therapy. Follow-up timing should also assess symptoms, tolerance, adherence, iron indices when useful, and whether the source is controlled.
Audit nonresponse
Verify the diagnosis, elemental exposure, schedule, interactions, adherence, ongoing bleeding, inflammation, malabsorption, and competing B12 or folate deficiency before calling treatment failure.
Quick check
Lesson
Make Oral Iron Absorbable and Livable
Oral iron works when the elemental dose, product, timing, interaction plan, tolerability strategy, storage, and follow-up fit the patient. Tablet strength alone does not state the active iron exposure.
- Elemental iron
- Ferrous salts
- Administration
- Chelation
- GI effects
- Overdose
Do not confuse salt mass with active iron content
Balance fasting exposure, food, acid, and a realistic routine
Protect levothyroxine, antibiotics, bisphosphonates, and integrase inhibitors
Check cause, dose, adherence, absorption, and ongoing loss before changing route
Calculate the active amount
Ferrous sulfate, gluconate, fumarate, carbonyl iron, polysaccharide complexes, and ferric products do not contain the same elemental fraction. Confirm the specific label rather than comparing salt milligrams.
Balance absorption and tolerance
Iron is often absorbed better away from food, but nausea, abdominal pain, constipation, or diarrhea can make that plan unsustainable. A lower frequency, different product, or administration with a small amount of food may improve persistence.
Protect interaction windows
Iron can chelate tetracyclines, fluoroquinolones, bisphosphonates, levothyroxine, and selected integrase inhibitors. Calcium, antacids, meals, tea, coffee, and chronic acid suppression can alter exposure. Use the exact interacting label for separation.
Counsel precisely
Dark stool can be expected, but tarry stool with weakness, pain, or bleeding risk still needs evaluation. Keep every iron product secured because pediatric ingestion can be fatal.
Know when the route no longer fits
Severe intolerance, unsatisfactory response, major malabsorption, continued loss that exceeds oral replacement, need for faster repletion, or a disease-specific indication can support intravenous therapy after the cause is reassessed.
Quick check
Lesson
Prescribe Intravenous Iron as an Exact Product
Intravenous iron can replete stores rapidly and bypass gastrointestinal absorption, but products differ in indication, dose, concentration, infusion time, visit burden, pediatric use, and important toxicities.
- Product selection
- Total course
- Hypersensitivity
- Hypophosphatemia
- Extravasation
- Monitoring
Match indication, weight, total course, concentration, and pediatric boundary
Use trained staff, emergency treatment, and product-specific observation
Track ferric carboxymaltose risk and product-specific toxicity
Avoid misleading early iron studies and automatic repeat courses
Match product to setting
Iron sucrose, ferric gluconate, ferric carboxymaltose, ferric derisomaltose, ferumoxytol, iron dextran, and dialysis-specific products are not operationally interchangeable. Compare approved indication, total course, visit burden, kidney setting, age, and payer access.
Prepare for hypersensitivity
Serious reactions are uncommon but possible. Administer in a setting with trained staff and immediate treatment, observe for the product-specific period, and document any prior infusion reaction by phenotype rather than using the vague label allergy.
Protect phosphate with ferric carboxymaltose
Current Injectafer labeling warns about symptomatic hypophosphatemia and osteomalacia, especially with repeated courses or predisposing conditions. Assess risk and monitor serum phosphate before repeat treatment when indicated.
Prevent administration injury
Follow exact dilution, concentration, infusion or push rate, and line instructions. Extravasation can cause persistent brown skin discoloration, so stop administration at the affected site.
Time the response
Document product, dose, date, reaction, CBC plan, iron-study timing, phosphate plan when relevant, and criteria for another course. Early assays can be distorted by recent parenteral iron.
Quick check
Lesson
Restore DNA Synthesis Without Missing Neurologic Injury
Vitamin B12 and folate deficiency can both produce megaloblastic anemia, but B12 deficiency can injure the nervous system. Treatment must protect neurologic function and resolve the cause, not only normalize the CBC.
- Vitamin B12
- Folate
- MMA
- Homocysteine
- Pernicious anemia
- Neuropathy
Use symptoms, methylmalonic acid, homocysteine, and cause
Use parenteral therapy when severity or absorption requires it
Never let folate mask untreated B12 neurologic disease
Lifelong replacement belongs to persistent causes, not every low result
Use metabolites thoughtfully
Methylmalonic acid and homocysteine can support a borderline B12 diagnosis, although kidney function affects methylmalonic acid. Folate deficiency elevates homocysteine without the same methylmalonic acid pattern.
Find the B12 cause
Diet, pernicious anemia, gastric surgery, ileal disease or resection, metformin, acid suppression, nitrous oxide, and other exposures alter risk. Neuropathy, gait change, cognitive symptoms, glossitis, or psychiatric change can occur before severe anemia.
Choose a reliable replacement route
Severe deficiency, neurologic disease, or substantial absorption failure favors parenteral loading. High-dose oral replacement can work in selected patients when adherence and passive absorption are reliable. Product regimens vary, so confirm the current label and clinical protocol.
Never let folate hide B12 disease
Folate may improve megaloblastic anemia while untreated B12-related neurologic injury continues. Check B12 status or provide appropriate B12 treatment when uncertainty remains.
Continue according to cause
Monitor reticulocyte and CBC response, symptoms, adherence, and cause control. Persistent causes such as pernicious anemia require durable replacement, while reversible causes need a documented reassessment.
Quick check
Lesson
Apply the Current CKD Anemia System
CKD anemia reflects reduced erythropoietin, iron restriction, blood loss, inflammation, dialysis, and comorbidity. The 2026 KDIGO guideline replaces the older one-threshold approach with population-specific iron and erythropoiesis decisions.
- KDIGO 2026
- Dialysis status
- Iron
- ESA
- HIF-PHI
- Hyporesponse
Exclude bleeding, nutrients, inflammation, hemolysis, and marrow disease
Use dialysis status, ferritin, TSAT, symptoms, and current treatment
Reduce transfusion exposure without normalizing hemoglobin
Treat iron restriction, inflammation, loss, nutrition, dialysis, or marrow disease
Do not attribute everything to CKD
Evaluate iron, B12, folate, reticulocytes, blood loss, dialysis losses, inflammation, hemolysis, marrow clues, and medication effects before labeling reduced erythropoietin as the sole cause.
Use the 2026 iron algorithm
Iron initiation differs across hemodialysis and nonhemodialysis populations. Use current ferritin and TSAT thresholds from KDIGO rather than the RxPrep summary of the 2012 guideline. Routine iron is reasonably withheld when ferritin is above 700 ng/mL or TSAT is at least 40 percent.
Select route with the patient
IV iron raises hemoglobin somewhat faster but brings infusion burden and rare serious reactions. Oral iron is inexpensive and accessible but often limited by gastrointestinal effects and adherence. Dialysis modality, access, preferences, response, and urgency shape the choice.
Use ESAs for a defined benefit
Correct reversible causes first. ESA therapy can reduce transfusions but can increase death, stroke, cardiovascular events, thrombosis, and access thrombosis. Use the lowest effective dose and do not pursue a normal hemoglobin.
Treat hyporesponse as a diagnostic problem
Iron restriction, inflammation, infection, blood loss, underdialysis, hyperparathyroidism, nutrient deficiency, marrow disease, and adherence should be assessed before repeated dose escalation. HIF-PHI use follows product indication and current guideline safeguards.
Quick check
Lesson
Recognize Destruction and Marrow Failure
Hemolysis accelerates red cell destruction, while aplastic and other marrow disorders reduce production across one or more cell lines. The smear, reticulocyte response, hemolysis pattern, exposure timeline, and other counts separate these high-risk pathways.
- Hemolysis
- DAT
- G6PD
- Drug triggers
- Aplastic anemia
- Pancytopenia
Combine reticulocytes, bilirubin, LDH, haptoglobin, smear, and DAT
Connect medicines, infection, transfusion, and inherited vulnerability
Aplastic anemia is not an isolated nutrient problem
Use symptoms, instability, bleeding, reserve, and patient values
Build the hemolysis pattern
Reticulocytosis, indirect bilirubin and LDH elevation, low haptoglobin, hemoglobinuria, and smear findings support hemolysis. The direct antiglobulin test helps classify immune involvement but does not replace the full pattern.
Connect a medicine to time and mechanism
Beta-lactams, ceftriaxone, piperacillin, methyldopa, rifampin, dapsone, primaquine, rasburicase, and other agents can contribute through different mechanisms. Stop a suspected severe trigger and obtain expert support.
Respect G6PD testing limits
Oxidant exposure, infection, and fava beans can trigger hemolysis in susceptible patients. An assay during an acute episode can be falsely normal because the most deficient older cells have already been destroyed, so repeat testing may be needed after recovery.
Recognize marrow failure
Aplastic anemia produces low reticulocytes with cytopenias and can cause life-threatening infection or bleeding. Medication, toxin, viral, immune, inherited, and malignant causes require urgent hematology and marrow evaluation.
Use supportive care deliberately
Transfusion, infection protection, bleeding management, immunosuppression, growth factors, or stem cell transplantation depend on the exact syndrome and severity. Empiric nutrient therapy cannot replace definitive evaluation.
Quick check
Lesson
Turn the Diagnosis Into a Closed-Loop Plan
A safe anemia plan names the working cause, treatment, source control, expected response, follow-up timing, adverse effects, failure rule, escalation trigger, and responsible clinician.
- Monitoring calendar
- Medication review
- Counseling
- Referral
- Source control
- Ownership
Find bleeding, suppression, hemolysis, depletion, and absorption effects
Use teach back for products, schedules, interactions, and danger signs
Time CBC and cause-specific studies to the expected response
Act on unexplained anemia, abnormal smear, pancytopenia, hemolysis, or failure
Preserve antibodies, effective analgesia, complications, and preferences
Establish adult care before pediatric care closes
Audit delays and solve barriers without blame
Assign every laboratory, vaccine, referral, and response review
Reconcile medication mechanisms
Antithrombotics and NSAIDs can promote bleeding. Acid suppression and metformin can alter nutrient exposure. Antimicrobials, chemotherapy, immunosuppressants, and other drugs can suppress marrow or trigger hemolysis. Link each exposure to a plausible mechanism and timeline.
Make monitoring decision linked
State when symptoms, CBC, reticulocytes, iron indices, B12 or folate markers, kidney function, phosphate, hemolysis tests, or other measures will change the plan. Record recent transfusion or infusion because timing affects interpretation.
Use teach back
Patients should know the cause being evaluated, exact product and schedule, administration, interaction windows, common effects, danger signs, missed-dose plan, and next laboratory or visit date.
Define failure and referral
Unexplained anemia, pancytopenia, abnormal smear, suspected marrow disease, severe hemolysis, recurrent iron loss, neurologic progression, or inadequate response requires escalation with the complete trend and prior work.
Assign ownership
Name who will review pending studies, evaluate the bleeding source, renew or stop treatment, manage infusion reactions, repeat a questionable test, and determine whether the anemia has truly resolved.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 144 question bank.
Each attempt draws a fresh set and rearranges the answer choices.